Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T12:55:22.525Z Has data issue: false hasContentIssue false
  • English
  • Français

Anaesthesia for electroconvulsive therapy – new tricks for old drugs: a systematic review

Published online by Cambridge University Press:  02 May 2017

Tobias Kvist Stripp ,
Martin Balslev Jorgensen  and
Niels Vidiendal Olsen
Tobias Kvist Stripp*
Affiliation:
Department of Neuroscience and Pharmacology, The Health Faculty, University of Copenhagen, Copenhagen, Denmark
Martin Balslev Jorgensen
Affiliation:
Psychiatric Centre Copenhagen, University Hospital of Copenhagen, Copenhagen, Denmark
Niels Vidiendal Olsen
Affiliation:
Department of Neuroscience and Pharmacology, The Health Faculty, University of Copenhagen, Copenhagen, Denmark Department of Neuroanaesthesia, The Neuroscience Centre, University Hospital of Copenhagen (Rigshospitalet), Copenhagen, Denmark
*
Tobias K Stripp, Department of Neuroscience and Pharmacology, The Health Faculty, University of Copenhagen, 3B Blegdamsvej, DK-2200 Copenhagen, Denmark. Tel: +45 22 42 25 80; Fax: +45 35 45 80 32 E-mail: tkstripp@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

The objective of this review is to investigate existing literature in order to delineate whether the use of anaesthesia and timing of seizure induction in a new and optimised way may improve the efficacy of electroconvulsive therapy (ECT).

Methods

PubMed/MEDLINE was searched for existing literature, last search on 24 June 2015. Relevant clinical studies on human subjects involving choice of anaesthetic, ventilation and bispectral index (BIS) monitoring in the ECT setting were considered. The references of relevant studies were likewise considered.

Results

Propofol yields the shortest seizures, etomidate and ketamine the longest. Etomidate and ketamine+propofol 1 : 1 seems to yield the seizures with best quality. Seizure quality is improved when induction of ECT is delayed until the effect of the anaesthetic has waned – possibly monitored with BIS values. Manual hyperventilation with 100% O2 may increase the pO2/pCO2-ratio, which may be correlated with better seizure quality.

Conclusion

Etomidate or a 1 : 1 ketamine and propofol combination may be the best method to achieve general anaesthesia in the ECT setting. There is a need for large randomised prospective studies comparing the effect of methohexital, thiopental, propofol, ketamine, propofol+ketamine 1 : 1 and etomidate in the ECT treatment of major depressed patients. These studies should investigate safety and side effects, and most importantly have antidepressant efficacy and cognitive side effects as outcome measures instead of seizure quality.

Keywords

consciousness monitorelectroconvulsive therapyhyperventilationintravenous anesthesia
Type
Review Article
Information
Acta Neuropsychiatrica , Volume 30 , Issue 2 , April 2018 , pp. 61 - 69
Check for updates
Copyright
© Scandinavian College of Neuropsychopharmacology 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Collins, PY, Patel, V, Joestl, SS et al. Grand challenges in global mental health. Nature 2011;475:27–30.Google Scholar
2. Sackeim, HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62:10–17.Google ScholarPubMed
3. Ruhe, HG, Huyser, J, Swinkels, JA, Schene, AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006;67:1836–1855.CrossRefGoogle ScholarPubMed
4. Baghai, TC, Moller, HJ, Rupprecht, R. Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharm Des 2006;12:503–515.CrossRefGoogle ScholarPubMed
5. Lisanby, SH, Maddox, JH, Prudic, J, Devanand, DP, Sackeim, HA. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry 2000;57:581–590.CrossRefGoogle ScholarPubMed
6. Chanpattana, W, Kramer, BA, Kunigiri, G, Gangadhar, BN, Kitphati, R, Andrade, C. A survey of the practice of electroconvulsive therapy in Asia. J ECT 2010;26:5–10.Google Scholar
7. Gilron, I, Delva, N, Graf, P et al. Canadian survey of perianesthetic care for patients receiving electroconvulsive therapy. J ECT 2012;28:219–224.Google Scholar
8. Bauer, J, Hageman, I, Dam, H et al. Comparison of propofol and thiopental as anesthetic agents for electroconvulsive therapy: a randomized, blinded comparison of seizure duration, stimulus charge, clinical effect, and cognitive side effects. J ECT 2009;25:85–90.Google Scholar
9. Nobler, MS, Sackeim, HA, Solomou, M, Luber, B, Devanand, DP, Prudic, J. EEG manifestations during ECT: effects of electrode placement and stimulus intensity. Biol Psychiatry 1993;34:321–330.Google Scholar
10. Swartz, CM. Disconnection of electroencephalographic, motoric, and cardiac evidence of ECT seizure. Convuls Ther 1996;12:25–30.Google Scholar
11. Roemer, RA, Shagass, C, Dubin, W, Jaffe, R, Katz, R. Relationship between pretreatment electroencephalographic coherence measures and subsequent response to electroconvulsive therapy: a preliminary study. Neuropsychobiology 1990;24:121–124.CrossRefGoogle ScholarPubMed
12. Perera, TD, Luber, B, Nobler, MS, Prudic, J, Anderson, C, Sackeim, HA. Seizure expression during electroconvulsive therapy: relationships with clinical outcome and cognitive side effects. Neuropsychopharmacology 2004;29:813–825.Google Scholar
13. Krystal, AD, Weiner, RD, Coffey, CE. The ictal EEG as a marker of adequate stimulus intensity with unilateral ECT. J Neuropsychiatry Clin Neurosci 1995;7:295–303.Google Scholar
14. Krystal, AD, Weiner, RD, Coffey, CE, McCall, WV. Effect of ECT treatment number on the ictal EEG. Psychiatry Res 1996;62:179–189.Google Scholar
15. Krystal, AD, Weiner, RD. ECT seizure therapeutic adequacy. Convuls Ther 1994;10:153–164.Google Scholar
16. Larson, G, Swartz, C, Abrams, R. Duration of ECT-induced tachycardia as a measure of seizure length. Am J Psychiatry 1984;141:1269–1271.Google Scholar
17. Gaines, GY 3rd, Rees, DI. Electroconvulsive therapy and anesthetic considerations. Anesth Analg 1986;65:1345–1356.CrossRefGoogle ScholarPubMed
18. Wagner, KJ, Mollenberg, O, Rentrop, M, Werner, C, Kochs, EF. Guide to anaesthetic selection for electroconvulsive therapy. CNS Drugs 2005;19:745–758.Google Scholar
19. Katzung, BG. Basic and clinical pharmacology, 10th edn. The McGraw-Hill Companies, New York City, New York, USA, p. 406–407.Google Scholar
20. Modica, PA, Tempelhoff, R, White, PF. Pro- and anticonvulsant effects of anesthetics (part II). Anesth Analg 1990;70:433–444.Google Scholar
21. Fredman, B, d’Etienne, J, Smith, I, Husain, MM, White, PF. Anesthesia for electroconvulsive therapy: effects of propofol and methohexital on seizure activity and recovery. Anesth Analg 1994;79:75–79.Google Scholar
22. Janouschek, H, Nickl-Jockschat, T, Haeck, M, Gillmann, B, Grozinger, M. Comparison of methohexital and etomidate as anesthetic agents for electroconvulsive therapy in affective and psychotic disorders. J Psychiatr Res 2013;47:686–693.CrossRefGoogle ScholarPubMed
23. Abdollahi, MH, Izadi, A, Hajiesmaeili, MR et al. Effect of etomidate versus thiopental on major depressive disorder in electroconvulsive therapy, a randomized double-blind controlled clinical trial. J ECT 2012;28:10–13.Google Scholar
24. Saffer, S, Berk, M. Anesthetic induction for ECT with etomidate is associated with longer seizure duration than thiopentone. J ECT 1998;14:89–93.CrossRefGoogle ScholarPubMed
25. Trapani, G, Altomare, C, Liso, G, Sanna, E, Biggio, G. Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem 2000;7:249–271.Google Scholar
26. Kotani, Y, Shimazawa, M, Yoshimura, S, Iwama, T, Hara, H. The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties. CNS Neurosci Ther 2008;14:95–106.CrossRefGoogle ScholarPubMed
27. Swaim, JC, Mansour, M, Wydo, SM, Moore, JL. A retrospective comparison of anesthetic agents in electroconvulsive therapy. J ECT 2006;22:243–246.Google Scholar
28. Eranti, SV, Mogg, AJ, Pluck, GC, Landau, S, McLoughlin, DM. Methohexitone, propofol and etomidate in electroconvulsive therapy for depression: a naturalistic comparison study. J Affect Disord 2009;113:165–171.Google Scholar
29. Vaidya, PV, Anderson, EL, Bobb, A, Pulia, K, Jayaram, G, Reti, I. A within-subject comparison of propofol and methohexital anesthesia for electroconvulsive therapy. J ECT 2012;28:14–19.Google Scholar
30. Rosa, MA, Rosa, MO, Belegarde, IM, Bueno, CR, Fregni, F. Recovery after ECT: comparison of propofol, etomidate and thiopental. Rev Bras Psiquiatr 2008;30:149–151.CrossRefGoogle ScholarPubMed
31. Ulusoy, H, Cekic, B, Besir, A, Geze, S, Hocaoglu, C, Akdogan, A. Sevoflurane/remifentanil versus propofol/remifentanil for electroconvulsive therapy: comparison of seizure duration and haemodynamic responses. J Int Med Res 2014;42:111–119.CrossRefGoogle ScholarPubMed
32. Geretsegger, C, Nickel, M, Judendorfer, B, Rochowanski, E, Novak, E, Aichhorn, W. Propofol and methohexital as anesthetic agents for electroconvulsive therapy: a randomized, double-blind comparison of electroconvulsive therapy seizure quality, therapeutic efficacy, and cognitive performance. J ECT 2007;23:239–243.Google Scholar
33. Purtuloglu, T, Ozdemir, B, Erdem, M et al. Effect of propofol versus sodium thiopental on electroconvulsive therapy in major depressive disorder: a randomized double-blind controlled clinical trial. J ECT 2013;29:37–40.Google Scholar
34. Patel, AS, Gorst-Unsworth, C, Venn, RM, Kelley, K, Jacob, Y. Anesthesia and electroconvulsive therapy: a retrospective study comparing etomidate and propofol. J ECT 2006;22:179–183.Google Scholar
35. Graveland, PE, Wierdsma, AI, van den Broek, WW, Birkenhager, TK. A retrospective comparison of the effects of propofol and etomidate on stimulus variables and efficacy of electroconvulsive therapy in depressed inpatients. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:230–235.Google Scholar
36. Lorrain, DS, Baccei, CS, Bristow, LJ, Anderson, JJ, Varney, MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003;117:697–706.Google Scholar
37. Hirshman, CA, Krieger, W, Littlejohn, G, Lee, R, Julien, R. Ketamine-aminophylline-induced decrease in seizure threshold. Anesthesiology 1982;56:464–467.Google Scholar
38. Rasmussen, KG, Jarvis, MR, Zorumski, CF. Ketamine anesthesia in electroconvulsive therapy. Convuls Ther 1996;12:217–223.Google Scholar
39. Fang, Y, Wang, X. Ketamine for the treatment of refractory status epilepticus. Seizure 2015;30:14–20.CrossRefGoogle ScholarPubMed
40. Niciu, MJ, Ionescu, DF, Richards, EM, Zarate, CA Jr.. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna) 2014;121:907–924.CrossRefGoogle ScholarPubMed
41. Hashimoto, K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009;61:105–123.Google Scholar
42. Berman, RM, Cappiello, A, Anand, A et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351–354.CrossRefGoogle ScholarPubMed
43. aan het Rot, M, Collins, KA, Murrough, JW et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139–145.CrossRefGoogle ScholarPubMed
44. Diazgranados, N, Ibrahim, L, Brutsche, NE et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793–802.Google Scholar
45. Ibrahim, L, Diazgranados, N, Franco-Chaves, J et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012;37:1526–1533.Google Scholar
46. Lapidus, KA, Levitch, CF, Perez, AM et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014;76:970–976.Google Scholar
47. Lara, DR, Bisol, LW, Munari, LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol 2013;16:2111–2117.CrossRefGoogle ScholarPubMed
48. Murrough, JW, Perez, AM, Pillemer, S et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013;74:250–256.Google Scholar
49. Murrough, JW, Iosifescu, DV, Chang, LC et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170:1134–1142.CrossRefGoogle ScholarPubMed
50. Papolos, DF, Teicher, MH, Faedda, GL, Murphy, P, Mattis, S. Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype. J Affect Disord 2013;147:431–436.Google Scholar
51. Zarate, CA Jr., Brutsche, NE, Ibrahim, L et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71:939–946.CrossRefGoogle ScholarPubMed
52. Zarate, CA Jr., Mathews, D, Ibrahim, L et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 2013;74:257–264.Google Scholar
53. Zarate, CA Jr., Singh, JB, Carlson, PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856–864.Google Scholar
54. Ibrahim, L, Diazgranados, N, Luckenbaugh, DA et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1155–1159.Google Scholar
55. Abelaira, HM, Reus, GZ, Neotti, MV, Quevedo, J. The role of mTOR in depression and antidepressant responses. Life Sci 2014;101:10–14.Google Scholar
56. Zunszain, PA, Horowitz, MA, Cattaneo, A, Lupi, MM, Pariante, CM. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry 2013;18:1236–1241.Google Scholar
57. Liu, RJ, Fuchikami, M, Dwyer, JM, Lepack, AE, Duman, RS, Aghajanian, GK. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013;38:2268–2277.Google Scholar
58. Pochwat, B, Palucha-Poniewiera, A, Szewczyk, B, Pilc, A, Nowak, G. NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Investig Drugs 2014;23:1181–1192.Google Scholar
59. Kavalali, ET, Monteggia, LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry 2012;169:1150–1156.Google Scholar
60. Wang, X, Chen, Y, Zhou, X, Liu, F, Zhang, T, Zhang, C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT 2012;28:128–132.Google Scholar
61. Yalcin, S, Aydogan, H, Selek, S et al. Ketofol in electroconvulsive therapy anesthesia: two stones for one bird. J Anesth 2012;26:562–567.Google Scholar
62. Erdogan Kayhan, G, Yucel, A, Colak, YZ et al. Ketofol (mixture of ketamine and propofol) administration in electroconvulsive therapy. Anaesth Intensive Care 2012;40:305–310.Google Scholar
63. Hoyer, C, Kranaster, L, Janke, C, Sartorius, A. Impact of the anesthetic agents ketamine, etomidate, thiopental, and propofol on seizure parameters and seizure quality in electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci 2014;264:255–261.CrossRefGoogle ScholarPubMed
64. Aksay, SS, Bumb, JM, Janke, C, Hoyer, C, Kranaster, L, Sartorius, A. New evidence for seizure quality improvement by hyperoxia and mild hypocapnia. J ECT 2014;30:287–291.Google Scholar
65. Hasselmann, HW. Ketamine as antidepressant? Current state and future perspectives. Curr Neuropharmacol 2014;12:57–70.Google Scholar
66. Kranaster, L, Kammerer-Ciernioch, J, Hoyer, C, Sartorius, A. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci 2011;261:575–582.Google Scholar
67. Vanlersberghe, C, Camu, F. Etomidate and other non-barbiturates. Handb Exp Pharmacol 2008;182:267–282.Google Scholar
68. Bergen, JM, Smith, DC. A review of etomidate for rapid sequence intubation in the emergency department. J Emerg Med 1997;15:221–230.Google Scholar
69. Wang, N, Wang, XH, Lu, J, Zhang, JY. The effect of repeated etomidate anesthesia on adrenocortical function during a course of electroconvulsive therapy. J ECT 2011;27:281–285.Google Scholar
70. Lebowitz, P. Etomidate is still a valid anesthetic for electroconvulsive therapy. J ECT 2014;30:261–262.Google Scholar
71. Singh, PM, Arora, S, Borle, A, Varma, P, Trikha, A, Goudra, BG. Evaluation of etomidate for seizure duration in electroconvulsive therapy: a systematic review and meta-analysis. J ECT 2015;31:213–225.Google Scholar
72. Chen, ST. Remifentanil: a review of its use in electroconvulsive therapy. J ECT 2011;27:323–327.Google Scholar
73. Hooten, WM, Rasmussen, KG Jr.. Effects of general anesthetic agents in adults receiving electroconvulsive therapy: a systematic review. J ECT 2008;24:208–223.Google Scholar
74. Hwang, JY, Kim, JH, Oh, AY, Do, SH, Jeon, YT, Han, SH. A comparison of midazolam with remifentanil for the prevention of myoclonic movements following etomidate injection. J Int Med Res 2008;36:17–22.Google Scholar
75. Baer, GA, Jantti, V, Rorarius, MG. Registration of raw data is a must when estimating depth of anaesthesia via EEG indices. Acta Anaesthesiol Scand 2006;50:1306; author reply 1306-7.Google Scholar
76. Gombar, S, Aggarwal, D, Khanna, AK, Gombar, KK, Chavan, BS. The bispectral electroencephalogram during modified electroconvulsive therapy under propofol anesthesia: relation with seizure duration and awakening. J ECT 2011;27:114–118.Google Scholar
77. Sartorius, A, Munoz-Canales, EM, Krumm, B et al. ECT anesthesia: the lighter the better? Pharmacopsychiatry 2006;39:201–204.Google Scholar
78. Kranaster, L, Hoyer, C, Janke, C, Sartorius, A. Bispectral index monitoring and seizure quality optimization in electroconvulsive therapy. Pharmacopsychiatry 2013;46:147–150.Google Scholar
79. Ochiai, R, Yamada, T, Kiyama, S, Nakaoji, T, Takeda, J. Bispectral index as an indicator of seizure inducibility in electroconvulsive therapy under thiopental anesthesia. Anesth Analg 2004;98:1030–1035.Google Scholar
80. Nishihara, F, Saito, S. Adjustment of anaesthesia depth using bispectral index prolongs seizure duration in electroconvulsive therapy. Anaesth Intensive Care 2004;32:661–665.Google Scholar
81. Suzuki, M, Edmonds, HL Jr., Tsueda, K, Malkani, AL, Roberts, CS. Effect of ketamine on bispectral index and levels of sedation. J Clin Monit Comput 1998;14:373.Google Scholar
82. Faraoni, D, Salengros, JC, Engelman, E, Ickx, B, Barvais, L. Ketamine has no effect on bispectral index during stable propofol-remifentanil anaesthesia. Br J Anaesth 2009;102:336–339.Google Scholar
83. Thimmaiah, R, Thirthalli, J, Ramesh, VJ et al. Effect of a course of electroconvulsive therapy on interictal bispectral index values: a prospective study. J ECT 2012;28:20–23.Google Scholar
84. Bridenbaugh, RH, Drake, FR, O’Regan, TJ. Multiple monitored electroconvulsive treatment of schizophrenia. Compr Psychiatry 1972;13:9–17.Google Scholar
85. Weiner, RD. The psychiatric use of electrically induced seizures. Am J Psychiatry 1979;136:1507–1517.Google Scholar
86. Bergsholm, P, Gran, L, Bleie, H. Seizure duration in unilateral electroconvulsive therapy. The effect of hypocapnia induced by hyperventilation and the effect of ventilation with oxygen. Acta Psychiatr Scand 1984;69:121–128.Google Scholar
87. Haeck, M, Gillmann, B, Janouschek, H, Grozinger, M. Electroconvulsive therapy can benefit from controlled hyperventilation using a laryngeal mask. Eur Arch Psychiatry Clin Neurosci 2011;261:S172–S176.Google Scholar
88. van Oppen, JD, Daniel, PS, Sovani, MP. What is the potential role of transcutaneous carbon dioxide in guiding acute noninvasive ventilation? Respir Care 2015;60:484–491.Google Scholar
89. Weiner, R. American Psychiatric Association Committee on electroconvulsive therapy. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging, 2nd edn. Washington, DC: American Psychiatric Press, 2001.Google Scholar
90. Lalla, FR, Milroy, T. The current status of seizure duration in the practice of electroconvulsive therapy. Can J Psychiatry 1996;41:299–304.Google Scholar
91. Simsek, GG, Zincir, S, Gulec, H, Eksioglu, S, Semiz, UB, Kurtulmus, YS. Do ictal EEG characteristics predict treatment outcomes in schizophrenic patients undergoing electroconvulsive therapy? Nord J Psychiatry 2015;69:466–471.Google Scholar